Managing Partner Michael Abrams spoke with Contract Pharma on the relationship between Big Pharma and smaller, technology-driven start-ups, and how it shapes development in the industry.

The idea that new and big pharma are competitors in the same race is, by and large, myth…the relationship between such companies has typically been synergistic.

Abrams also touched on the future of M&A, citing the pace of innovation, patent cliffs, and the Inflation Reduction Act as reasons to expect increased levels of M&A activity.

Read the full story at Contract Pharma.